Aktienanalyse zu Immutep Ltd (IMMP)IMMPImmutep Ltd

Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Immutep Ltd (IMMP) is a good buy right now due to its recent FDA Orphan Drug Designation for Eftilagimod Alfa, which significantly enhances its market potential. The current price of $3.18 is well below its 52-week high of $70.60, indicating substantial upside potential. Additionally, the stock has shown a recent positive momentum with a 5-day change of +3.92% and a remarkable 18.22% increase yesterday, signaling strong market interest. However, the stock is still down 94.61% year-to-date, highlighting the risks associated with its volatility and recent trial failures. The forward P/E ratio of 7.13 suggests that the stock may be undervalued relative to its future earnings potential, making it an attractive long-term investment despite the inherent risks.

1 analysts cover IMMP: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.